Information Provided By: 
Fly News Breaks for May 30, 2019
PCRX, HRTX
May 30, 2019 | 08:37 EDT
Jefferies analyst Biren Amin raised his price target for Heron Therapeutics (HRTX) to $37 from $35 after conducting an expert survey prior to the company's FDA action date. The analyst's survey of 50 U.S. doctors suggests HTX-011 would capture the majority of its share from generic bupivacaine, with the remainder from Pacira's (PCRX) Exparel. Importantly, doctors view the opioid-sparing effect of TX-011 as compelling, Amin tells investors in a research note. HE keeps a Buy rating on the shares.
News For HRTX;PCRX From the Last 2 Days
There are no results for your query HRTX;PCRX
